Bristol Myers Squibb presented new 56-week clinical data for its drug Camzyos (mavacamten) in pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions. The Phase 3 SCOUT-HCM trial evaluated the safety and efficacy of the treatment over a longer duration than previously reported, confirming consistent performance in this younger demographic. The study included 44 randomized patients aged 12 to under 18, with 43 completing the double-blind placebo-controlled period. Results showed that patients receiving Camzyos achieved a mean reduction of 48.1 mmHg in the Valsalva left ventricular outflow tract gradient after 56 weeks. Patients who switched from placebo to active treatment demonstrated similar degrees of improvement, indicating robust therapeutic response. Safety profiles remained stable throughout the evaluation period, with no patient experiencing a left ventricular ejection fraction below 50%. The company reported no new safety signals and noted that treatment-emergent adverse events and serious events remained low. This data supports the September 2026 FDA approval for pediatric patients weighing at least 30 kilograms and strengthens the drug's developing profile in this specific market segment. Further presentations regarding Camzyos are scheduled for the American Heart Association Scientific Sessions through November 9, covering additional clinical and real-world evidence in adult patients. These upcoming events will provide further context on long-term safety and effectiveness analyses, complementing the new pediatric findings presented in Chicago.